To improve the awareness of early screening for diabetic kidney disease, and achieve early detection, early intervention, and early treatment, Aiwei Technology, and AstraZeneca announced during the 2021 Taihu Bay Life and Health Future Conference that the two parties will officially launch strategic cooperation. Extensive screening of patients with the early renal disease will enhance the awareness of doctors and patients on the prevention and treatment of kidney and other target organ damage caused by diabetes, promote standardized management of the entire course of diabetes, and help build a healthy China.
Many patients with diabetic nephropathy have low awareness and treatment rates
The latest epidemiological survey data show that the prevalence rate of type 2 diabetes in my country is as high as 11.2%. Diabetic nephropathy is one of the main microvascular complications. About 20%-40% of diabetic patients with diabetic nephropathy have become chronic kidney disease and end-stage. The main cause of kidney disease, compared with patients without diabetic nephropathy, patients with diabetic nephropathy have a higher mortality rate. Risk factors for diabetic nephropathy include advanced age, gender, race, long-term disease, high blood sugar, high blood pressure, obesity, high-salt diet, dyslipidemia, nephrotoxic substances, acute kidney injury, excessive protein intake, etc.
Studies have shown that the awareness rate of diabetic nephropathy in my country is less than 20%, and the treatment rate is less than 50%. The early symptoms of diabetic nephropathy are hidden and difficult to be detected, causing a large number of patients to miss the best time for diagnosis and treatment. As the course of the disease is prolonged, the kidneys may be progressively damaged, and may even cause renal failure. This not only affects the patient’s quality of life, but also has a long treatment cycle The cost is high, which brings a serious economic burden to patients, families, and society.
Early prevention and treatment of diabetic nephropathy is the key, UACR testing is very important The prevention and treatment of diabetic nephropathy are divided into three stages. The first stage is to prevent the occurrence of diabetic nephropathy, including early screening, lifestyle changes, and blood sugar and blood pressure control. The second stage is early treatment. Patients with diabetic nephropathy who have albuminuria or predicted glomerular filtration rate should be treated with comprehensive treatment, such as optimizing blood sugar and blood pressure to reduce or delay the occurrence of end-stage renal disease. The third stage is the comprehensive treatment for advanced diabetic nephropathy, including renal replacement therapy, prevention, and treatment of related complications, and reducing the risk of cardiovascular events and death. Early diagnosis, prevention, and delay of the occurrence and development of diabetic nephropathy are of great significance for reducing the occurrence of macrovascular events, increasing the survival rate of patients, and improving the quality of life. It can also greatly save medical expenses.
The prevention and treatment of diabetic nephropathy emphasize active screening, early detection, and comprehensive intervention. The relevant guidelines formulated by the Diabetes Branch of the Chinese Medical Association point out that patients with type 2 diabetes can be accompanied by nephropathy at the time of diagnosis, and nephropathy screening should be performed immediately after diagnosis of type 2 diabetes. Check and monitor regularly according to the condition. In the prediction of early kidney damage, urinary albumin/creatinine ratio (UACR) is an important early warning factor, which can reflect the degree of kidney damage as early as possible. Through rapid detection of UACR in diabetic patients, it can help early detection of diabetic nephropathy, intervention, and treatment, and delay the disease. Progress has important guiding significance.
Aiwei Technology joins hands with AstraZeneca to promote early screening and early diagnosis of diabetic nephropathy Aiwei Technology has more than 20 years of professional experience in the field of urine testing, providing urine testing products and services to more than 4,000 professional medical institutions across the country, and is well recognized by users with its disruptive technological innovation and excellent quality. Aiwei Technology expects that professional testing products and services will widely benefit primary medical institutions and individual users, and will help build a "healthy China" and realize the vision of "allowing people to enjoy modern medical services". AstraZeneca has more than 40 years of global experience in the field of kidney disease. It is patient-centric, insists on science first, focuses on innovation, and is committed to providing comprehensive solutions for chronic disease management. It hopes to contribute to the prevention and treatment of kidney disease in China. China promises. The "Healthy China Action (2019-2030)" pointed out that the goal of diabetes prevention and treatment is: by 2030, the standard management rate of diabetes patients is expected to reach 70% or above, and the rate of diabetes treatment, diabetes control, and diabetes complication screening rates will continue to increase. Aiwei Technology and AstraZeneca actively respond to national policies. Under the guidance of the National Health Commission, promote metabolic diseases and their complications, raise awareness of prevention and treatment of target organ damage such as kidneys, and strengthen the prevention and treatment of diabetic nephropathy through extensive UACR testing. Early screening, early detection, and active and effective intervention measures are adopted to standardize the comprehensive management of metabolic diseases, reduce the morbidity and mortality of diabetic patients, improve the quality of life, extend the life span, and help build a healthy China. Also, Aiwei Technology and AstraZeneca will also strengthen the international cooperation and promotion of the two parties in the early screening of diabetic nephropathy, aiming to "enable the Chinese people to enjoy modern medical services" and "deepen China's commitment" at the same time as the early screening of diabetic nephropathy The experience of early intervention and early treatment is extended to countries along the “Belt and Road” such as Singapore, Malaysia, Indonesia, Vietnam, and the Philippines, benefiting more patients, using health to hold and tie the emotions of people along the route and work together to help build a human health community.
Comments
Post a Comment